JNJ 18038683

Drug Profile

JNJ 18038683

Alternative Names: JNJ-18038683

Latest Information Update: 04 Feb 2016

Price : $50

At a glance

  • Originator Janssen Research & Development
  • Developer Janssen Research & Development; Northwestern University
  • Class Antidepressants
  • Mechanism of Action Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bipolar disorders
  • Discontinued Major depressive disorder

Most Recent Events

  • 01 Sep 2015 Phase-II clinical trials in Bipolar disorders in USA (unspecified route) (NCT02466685)
  • 01 Dec 2011 Discontinued - Phase-II for Major depressive disorder in USA (PO)
  • 01 Dec 2008 Janssen Research & Development completes a phase IIa trial in Major depressive disorder in USA (NCT00566202)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top